Vc-MMAD

For research use only. Not for therapeutic Use.

  • CAT Number: I001535
  • CAS Number: 1401963-17-4
  • Molecular Formula: C70H104N12O14S
  • Molecular Weight: 1369.71
  • Purity: ≥95%
Inquiry Now

Vc-MMAD(Cat No.:I001535)is a potent cytotoxic agent used in antibody-drug conjugates (ADCs) for targeted cancer therapy. It consists of monomethyl auristatin D (MMAD), a synthetic antimitotic agent that inhibits tubulin polymerization, linked to a valine-citrulline (Vc) dipeptide. The Vc linker ensures that MMAD remains inactive until it is released inside target cancer cells through protease cleavage. Once released, MMAD disrupts cell division, leading to apoptosis. Vc-MMAD is commonly researched in oncology for its ability to selectively kill cancer cells while minimizing damage to healthy tissues, making it a promising therapeutic strategy.


Catalog Number I001535
CAS Number 1401963-17-4
Synonyms

(Z)-N-((S,Z)-1-(((S)-1-((4-((5S,8S,11S,12R,Z)-11-((S)-sec-butyl)-6-hydroxy-12-(2-((S)-2-((1R,2R,Z)-3-hydroxy-1-methoxy-2-methyl-3-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)imino)propyl)pyrrolidin-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,9-dioxo-2

Molecular Formula C70H104N12O14S
Purity ≥95%
Target Microtubule/Tubulin
Solubility 10 mM in DMSO
Storage Store at -20°C
IC50 N/A
IUPAC Name [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
InChI InChI=1S/C70H104N12O14S/c1-14-45(8)61(53(94-12)40-57(86)81-37-22-26-52(81)62(95-13)46(9)63(87)76-51(67-72-35-38-97-67)39-47-23-17-15-18-24-47)79(10)68(91)59(43(4)5)78-66(90)60(44(6)7)80(11)70(93)96-41-48-28-30-49(31-29-48)74-64(88)50(25-21-34-73-69(71)92)75-65(89)58(42(2)3)77-54(83)27-19-16-20-36-82-55(84)32-33-56(82)85/h15,17-18,23-24,28-33,35,38,42-46,50-53,58-62H,14,16,19-22,25-27,34,36-37,39-41H2,1-13H3,(H,74,88)(H,75,89)(H,76,87)(H,77,83)(H,78,90)(H3,71,73,92)/t45-,46+,50-,51-,52-,53+,58-,59-,60-,61-,62+/m0/s1
InChIKey GRBICHHPFYWKKI-BDVWXETGSA-N
SMILES CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC4=CC=C(C=C4)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN5C(=O)C=CC5=O
Reference

<p style=/line-height:25px/>
<br>[1]. Antibody-drug conjugates Patent: WO 2013068874 A1
</p>

Request a Quote